TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38578686
Drug: Self-guided lifestyle
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-guided lifestyle intervention (12-week duration, including 1 virtual group session, digital tools, access to self-paced web- and mobile-based content, and 12 weekly health risk text messages)
Study: 38579297
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg of elemental oral iron as ferrous sulfate
Study: 38579297
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of elemental oral iron as ferrous sulfate
Study: 38579297
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of elemental oral iron as ferrous sulfate
Study: 38579297
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg of elemental oral iron as ferrous sulfate
Study: 38579300
Drug: In-hospital intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital intervention (evaluation of inhalation technique and PIF, provision of a written guide, therapeutic education)
Study: 38579315
Drug: NSAID-based pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID-based pain control (oral acetaminophen and intravenous ketorolac)
Study: 38580007
Drug: Serum uric
Normalized name: Uric acid
DrugBank: Uric acid (DB08844)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum uric acid levels (dose-response analysis)
Study: 38580350
Drug: Any treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any treatment (conventional or biological antirheumatic treatment)
Study: 38580355
Drug: Alpha-2 agonists
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-2 agonists (clonidine and dexmedetomidine)
Study: 38580373
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (pharmacological nutritional hypercaloric products)
Study: 38580386
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg vedo-800CW
Study: 38580386
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg vedo-800CW after unlabelled vedolizumab
Study: 38580386
Drug: 4.5 mg
Normalized name: phenol 14.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.5 mg vedo-800CW
Study: 38580444
Drug: Monthly emailed
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly emailed behavioural 'nudge' messages encouraging compliance with social norms and clinical guidelines around prescribing.
Study: 38581534
Drug: Eribulin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin and AIs (combined treatment)
Study: 38581616
Drug: Donanemab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donanemab (700 mg for three doses, then 1400 mg/dose, intravenous every 4 weeks for 72 weeks)
Study: 38581739
Drug: Psilocybin pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin pulse (10 mg/70 kg, 3 doses, 5 days apart)
Study: 38581842
Drug: Sitagliptin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin with basal-plus (BP) insulin regimen
Study: 38581926
Drug: Variable tidal
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variable tidal volume (6 ml/kg PBW ± 33% at 5-min intervals)
Study: 38581926
Drug: Fixed tidal
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed tidal volume (6 ml/kg PBW)
Study: 38582092
Drug: Docetaxel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (75 mg/m²) in group A
Study: 38582092
Drug: Chemotherapy-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy-free treatment with trastuzumab and pertuzumab in group B
Study: 38582271
Drug: Vonoprazan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan (20 mg twice a day for 3 days, then 20 mg once a day for 28 days)
Study: 38582271
Drug: High-dose PPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PPI (pantoprazole intravenous infusion 8 mg/h for 3 days, then omeprazole 20 mg twice a day for 28 days)
Study: 38582540
Drug: Placebo (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (chemotherapy only)
Study: 38582650
Drug: Olaparib plus
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib plus abiraterone (300 mg bid + 1000 mg od)
Study: 38582650
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus abiraterone (placebo + 1000 mg od)
Study: 38582713
Drug: Lenvatinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib plus Pembrolizumab (L + P)
Study: 38582934
Drug: Robotic-assisted early
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic-assisted early mobilization (20 min, twice daily during the first week in ICU)
Study: 38583091
Drug: Standard-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose quadrivalent inactivated influenza vaccine
Study: 38583092
Drug: Plozasiran (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plozasiran (10, 25, or 50 mg)
Study: 38583146
Drug: Simultaneous virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP1-RA
Study: 38583146
Drug: Education-First (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education-First (2 months of virtual education followed by medication prescription)
Study: 38583185
Drug: Telephone-based telehealth
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based telehealth model for guideline-directed medical therapy initiation and titration.
Study: 38583289
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg subcutaneously every 4 weeks
Study: 38583316
Drug: Non-hormonal pessary
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormonal pessary applied once daily for the first 7 days and twice a week for the subsequent 31 days
Study: 38583450
Drug: Stable-dose conventional
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable-dose conventional synthetic DMARDs (n=80)
Study: 38583450
Drug: Half-dose conventional
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose conventional synthetic DMARDs (n=42)
Study: 38583450
Drug: Half-dose conventional
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose conventional synthetic DMARDs tapering to withdrawal (n=38)
Study: 38583455
Drug: Remission induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission induction with high-dose cytarabine (3 g/m²)
Study: 38583491
Drug: JNJ-3989 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-3989 (200 mg subcutaneously every 4 weeks) + JNJ-6379 (250 mg oral daily) + NA (oral daily)
Study: 38583540
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg/day for 4 weeks starting on the third day after RFA)
Study: 38583540
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (historical control, RFA without oral steroids)
Study: 38583715
Drug: Scheduled analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled analgesia (paracetamol 1 g + ibuprofen 400 mg every 6 hours for the first 24 hours postpartum)
Study: 38583720
Drug: Radical radiotherapy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical radiotherapy and local treatment of metastases
Study: 38583720
Drug: Maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance therapy after radiotherapy
Study: 38584159
Drug: Quadpill (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadpill (candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg)
Study: 38584166
Drug: Personalized therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized therapeutic cancer vaccine (PTCV) GNOS-PV02 coadministered with plasmid-encoded interleukin-12 plus pembrolizumab
Study: 38584600
Drug: Fuke Qianjin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuke Qianjin capsule, dosage and duration not available
Study: 38585206
Drug: TAR-200 treatment
Normalized name: coal tar 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAR-200 treatment (two 7-day or two 21-day dosing cycles)
Study: 38585206
Drug: TAR-200 treatment
Normalized name: coal tar 200 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAR-200 treatment
Study: 38997620
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg daily for 12 months
Study: 38586018
Drug: Calorie absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calorie absorption assessment
Study: 38586120
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of megestrol acetate (625 mg/5 mL)
Study: 38586120
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of megestrol acetate (625 mg/5 mL)
Study: 38586278
Drug: Mandatory twice-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory twice-weekly evaluations
Study: 38586278
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care weekly clinical evaluations with ad hoc supplemental evaluations
Study: 38586479
Drug: High-dose RBT-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose RBT-1 (90 mg SnPP/240 mg FeS)
Study: 38586479
Drug: Low-dose RBT-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RBT-1 (45 mg SnPP/240 mg FeS)
Study: 38586479
Drug: High-dose RBT-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose RBT-1
Study: 38586479
Drug: Low-dose RBT-1
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose RBT-1
Study: 38587033
Drug: LP-PRP injection
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP-PRP injection during surgery (5-mL dose)
Study: 38587079
Drug: 10E8VLS (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10E8VLS (5 mg/kg)
Study: 38587079
Drug: 10E8VLS and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10E8VLS and VRC07-523LS (5 mg/kg each)
Study: 39217567
Drug: Semaglutide (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide (2.4 mg once weekly)
Study: 38587249
Drug: 80-mg olezarsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-mg olezarsen
Study: 38587249
Drug: 50-mg olezarsen
Normalized name: Olezarsen
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg olezarsen
Study: 38587241
Drug: Beta-blocker treatment
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker treatment (metoprolol or bisoprolol)
Study: 39221651
Drug: CSL112 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSL112 (6 g, four weekly infusions)
Study: 38587276
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (E2) gel + ADT
Study: 38587329
Drug: Customizable sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customizable sequential digital cognitive aid (DCA) with ILCOR algorithm poster displayed on the wall
Study: 38587333
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (control)
Study: 38587380
Drug: Dolutegravir/lamivudine FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir/lamivudine FDC (50 mg dolutegravir and 300 mg lamivudine)
Study: 38587645
Drug: Toludesvenlafaxine hydrochloride
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toludesvenlafaxine hydrochloride 9 mg/kg (i.v.) followed by 3 mg/kg infusion via minipump
Study: 38587645
Drug: Toludesvenlafaxine hydrochloride
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toludesvenlafaxine hydrochloride 32 mg/kg oral administration
Study: 38587643
Drug: trastuzumab-pertuzumab and
Normalized name: hyaluronidase / pertuzumab / trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: trastuzumab-pertuzumab and chemotherapy de-escalation
Study: 38587822
Drug: Zerlasiran 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 300 mg
Study: 38587822
Drug: Zerlasiran 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 600 mg
Study: 38587822
Drug: Zerlasiran 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 200 mg (two doses)
Study: 38587822
Drug: Zerlasiran 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 300 mg (two doses)
Study: 38587822
Drug: Zerlasiran 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 450 mg (two doses)
Study: 38587852
Drug: Naked-eye 3-dimensional
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naked-eye 3-dimensional vision training (NVT) for 20 minutes daily
Study: 38587881
Drug: Individual psychotherapy
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual psychotherapy (treatment as usual, no postsession questionnaires)
Study: 38588480
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg methylprednisolone i.v./d plus erythropoietin (33,000 IU/d) for 3 days
Study: 38588480
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg methylprednisolone i.v./d plus placebo (saline solution) for 3 days
Study: 38588588
Drug: Placebo arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm (placebo antibiotic/placebo microbiome modulation + nivolumab)
Study: 38588682
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy consisting of paclitaxel (80 mg/m2)
Study: 38588696
Drug: Neoadjuvant olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant olaparib with chemotherapy
Study: 38589574
Drug: Concurrent inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent inhibition of oncogenic and wild-type RAS-GTP
Study: 38589856
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with gemcitabine, cisplatin, and nabpaclitaxel (GAP)
Study: 38589856
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with GAP
Study: 38589926
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX), 2-4 cycles before surgery and 4-6 cycles after surgery.
Study: 38589926
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX), 8 cycles after upfront surgery.
Study: 38589926
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PC) with S-1 plus oxaliplatin (SOX).
Study: 38589926
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (AC) with S-1 plus oxaliplatin (SOX).
Study: 38590283
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment using the heparin-bonded Viabahn endoprosthesis
Study: 38590716
Drug: Consolidation chemoradiation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemoradiation (CTRT) with concurrent capecitabine at 1250 mg/m2
Study: 38590831
Drug: 15g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15g of specific collagen peptides (SCP) daily
Study: 38591260
Drug: Mavacamten, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavacamten, 5 mg once daily with individualized dose titration at week 6
Study: 38591748
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase within 4.5 hours of symptom onset
Study: 38591808
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose at the extraction site
Study: 38591811
Drug: Mibavademab (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibavademab (0.3, 1.0, 3.0, 10, and 30 mg/kg i.v. or 300 and 600 mg subcutaneous)
Study: 38591811
Drug: Mibavademab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mibavademab (15 mg/kg i.v. loading dose and 10 mg/kg i.v. at weeks 3, 6, and 9)
Study: 38591829
Drug: iFightDepression-SURVIVE (iFD-S)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iFightDepression-SURVIVE (iFD-S) with treatment as usual (TAU)
Study: 38591997
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of coronary artery calcium score (Ca-score) and high-sensitivity cardiac troponin T (hs-cTnT)
Study: 38593233
Drug: Posoleucel infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posoleucel infusion initiated within 15 to 49 days of allo-HCT, subsequently every 14 days for up to 7 doses.
Study: 38593233
Drug: Posoleucel infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Posoleucel infusion
Study: 38593241
Drug: Pegcetacoplan therapy
Normalized name: Pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegcetacoplan therapy
Study: 38593249
Drug: Nicotinamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1 g/day)
Study: 38593348
Drug: RMC-6236 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-6236 at 300 mg daily
Study: 38593348
Drug: RMC-6236 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-6236 at 100 mg and 300 mg daily
Study: 38593512
Drug: Adavosertib 250
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 250 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Study: 38593512
Drug: Adavosertib 200
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 200 mg once daily for 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle
Study: 38593947
Drug: Inclisiran (284
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inclisiran (284 mg at days 0, 90, and 270) plus usual care
Study: 38594150
Drug: Renal Replacement
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal Replacement Therapy (RRT)
Study: 38594150
Drug: Norepinephrine/Epinephrine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine/Epinephrine treatment
Study: 38594245
Drug: WU-04 (non-covalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: WU-04 (non-covalent inhibitor)
Study: 38594245
Drug: Ensitrelvir and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensitrelvir and nirmatrelvir (clinically used inhibitors)
Study: 38594435
Drug: Increasing adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increasing adalimumab (ADA) dose intervals to 3 and then to 4 weeks.
Study: 38594435
Drug: Increasing adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Increasing adalimumab (ADA) dose intervals.
Study: 38594603
Drug: GARD-optimized doses
Normalized name: Eco-Gard
Approvals — FDA: no, EMA: no, PMDA: no
Description: GARD-optimized doses with simultaneous integrated boost (SIB) doses of 70 and 60 Gy in 25 fractions to the highest and intermediate radioresistant habitats, while the remaining volume receives standard 50 Gy
Study: 38594603
Drug: mpMRI taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: mpMRI taken between weeks two and three of treatment
Study: 38594727
Drug: Unsupervised robot-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unsupervised robot-assisted therapy
Study: 38594725
Drug: CBT-I with
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-I with bright light therapy
Study: 38594737
Drug: Functional-Cognitive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-Cognitive and Sensory Treatment (F-CaST)
Study: 38594905
Drug: Sintilimab plus
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab plus chemotherapy (Sin+Chemo)
Study: 38597172
Drug: Low-dose ticagrelor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ticagrelor (60 mg twice a day)
Study: 38597172
Drug: Clopidogrel (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (75 mg once a day)
Study: 38597214
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG) receiving 8 mg cyproheptadine and 5 mg prazosin ER daily
Study: 38597214
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG) receiving 12 mg cyproheptadine and 10 mg prazosin ER daily
Study: 38597399
Drug: Ablation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablation plus systemic therapy (AS)